Cardio Diagnostics Holdings, Inc. (CDIO)
| Market Cap | 5.42M -80.0% |
| Revenue (ttm) | 14,825 -57.5% |
| Net Income | -6.50M |
| EPS | -3.71 |
| Shares Out | 2.96M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 48,014 |
| Open | 1.856 |
| Previous Close | 1.810 |
| Day's Range | 1.830 - 1.940 |
| 52-Week Range | 0.970 - 7.910 |
| Beta | 2.26 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 13, 2026 |
About CDIO
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic... [Read more]
Financial Performance
In 2025, CDIO's revenue was $14,825, a decrease of -57.51% compared to the previous year's $34,890. Losses were -$6.50 million, -22.49% less than in 2024.
Financial StatementsNews
CORRECTING and REPLACING Cardio Diagnostics Holdings, Inc. to Host Investor Call on Thursday, February 19, 2026
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will host an investor conference call on Thursday, February 19, 2026, at 3 p.m. Central Time.
Cardio Diagnostics Holdings, Inc. to Host Investor Call on Wednesday, February 18, 2026
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will host an investor conference call on Wednesday, February 18, 2026, at 3 p.m. Central Time.
Cardio Diagnostics, Aimil Ltd. and Dr. Lal PathLabs Limited Partner to Launch the PrecisionCHD™ Test in India
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics, Aimil Ltd., and Dr. Lal PathLabs announce strategic agreement to launch Cardio Diagnostics' PrecisionCHD™ test in India.
Cardio Diagnostics Holdings, Inc. and Southdale YMCA Announce New Heart Health Partnership to Serve the Edina, Minnesota Community
EDINA, Minn. & CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced a partnership with the Southdale YMCA, becoming the second YMCA location nationally to partner with Cardio Diagnostics.
Cardio Diagnostics gets gapfill payment rate for Epi+Gen, Precision CHD tests
Cardio Diagnostics (CDIO) announced that the Centers for Medicare and Medicaid Services has issued a final gapfill payment rate of $854 for both the Epi+Gen CHD and PrecisionCHD tests. This
Cardio Diagnostics Receives Final Gapfill Payment Rates for AI-Driven Cardiovascular Tests from the Centers for Medicare and Medicaid Services (CMS)
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced that CMS has issued a final gapfill payment rate of $854 for both the Epi+Gen CHD™ and PrecisionCHD™ tests.
Cardio Diagnostics Holdings, Inc. to Present Data Demonstrating PrecisionCHD's Ability to Detect INOCA and MINOCA at the American Heart Association Scientific Sessions
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will be presenting new data at the American Heart Association (AHA) Scientific Sessions.
Cardio Diagnostics Holdings, Inc. and YMCA of East Tennessee Partner to Bring Heart Health Education and Advanced Testing to East Tennessee Community
KNOXVILLE, Tenn. & CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced they are partnering with YMCA of East Tennessee to launch a customized program exclusively for its members.
Cardio Diagnostics Holdings, Inc. Expands Provider Network, Adding 15 New Provider Organizations From Across the United States
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. today announced the Company has partnered with 15 new provider organizations across the United States.
Cardio Diagnostics gets CMS gapfill payment rates for cardiovascular tests
Cardio Diagnostics (CDIO) announced that the Centers for Medicare and Medicaid Services, through the MolDX program, has issued preliminary gapfill payment rates of $350 for Epi+Gen CHD and $684.76 for
Cardio Diagnostics Receives Gapfill Payment Rates for AI-Driven Cardiovascular Tests from the Centers for Medicare and Medicaid Services (CMS)
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics CMS has issued preliminary gapfill payment rates of $350 for Epi+Gen CHD™ and $684.76 for PrecisionCHD™.
Cardio Diagnostics, AGEPHA Pharma in deal for heart disease study
Cardio Diagnostics (CDIO) Holdings and AGEPHA Pharma announced an agreement that will enable the validation of a precision-guided approach to treating inflammation-driven coronary heart disease. AGEPH...
Cardio Diagnostics Enters Into an Agreement with AGEPHA Pharma to Advance Precision Assessment and Management of Inflammation Associated with Coronary Heart Disease
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced an agreement with AGEPHA Pharma.
Cardio Diagnostics secures Japanese patent for set of biomarkers
Cardio Diagnostics (CDIO) announced that the Japan Patent Office has issued a patent for another set of biomarkers in the company’s intellectual property portfolio. The patent is exclusively licensed ...
Cardio Diagnostics Secures Japanese Patent for AI-Driven Cardiovascular Disease Detection Technology
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced that the Japan Patent Office has issued a patent for another set of biomarkers in the company's IP portfolio.
Cardio Diagnostics regains compliance with Nasdaq
Cardio Diagnostics (CDIO) announced that it received a notification letter from Nasdaq notifying the company that it had regained compliance with the minimum bid price requirement set forth in the
Cardio Diagnostics Holdings, Inc. Regains Compliance with Nasdaq Minimum Bid Price
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced it has regained compliance with Nasdaq minimum bid price.
Cardio Diagnostics Broadens Access to Precision Cardiovascular Care with New Practice Partnerships Across U.S. Mainland and Puerto Rico
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics has the continued expansion of its reach with a new cohort of healthcare practices across the United States.
Cardio Diagnostics Holdings Inc trading resumes
13:00 EDT Cardio Diagnostics (CDIO) Holdings Inc trading resumes
Cardio Diagnostics Holdings Inc trading halted, volatility trading pause
12:55 EDT Cardio Diagnostics (CDIO) Holdings Inc trading halted, volatility trading pause
Cardio Diagnostics Holdings Inc trading halted, news pending
19:50 EDT Cardio Diagnostics (CDIO) Holdings Inc trading halted, news pending
Cardio Diagnostics announces 1-for-30 reverse stock split
Cardio Diagnostics (CDIO) announced a 1-for-30 reverse stock split of its common stock effective with the market opening on May 13. The reverse stock split will take effect at 11:59
Cardio Diagnostics Holdings, Inc. Announces 1-for-30 Reverse Stock Split
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings today announced a 1-for-30 reverse stock split of its common stock effective with the market opening on May 13, 2025.
Cardio Diagnostics Holdings, Inc. to Showcase Enhanced PrecisionCHD™, Actionable Clinical Intelligence™ and New Clinical Advancements at the American College of Cardiology's 74th Annual Scientific Session
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will showcase its growing portfolio of advanced cardiovascular solutions at the ACC's 74th Annual Scientific Session & Expo.
Cardio Diagnostics files $50M mixed securities shelf
16:35 EST Cardio Diagnostics (CDIO) files $50M mixed securities shelf